TORONTO, Ontario, May 31, 2021 – Auxly Cannabis Group Inc. (TSX- XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“) announced today that it will hold its Annual General and Special Meeting of Shareholders (the “Meeting”) on Monday, June 28, 2021 at 2:00 p.m. EST at the offices of Bennett Jones LLP, 3400 One First Canadian Place, Toronto, Ontario, M5X 1A4. 

COVID-19 Guidance

The Company is strongly discouraging physical attendance at the meeting to proactively deal with potential issues arising from the unprecedented public health impact of COVID-19 and to limit and mitigate risks to the health and safety of its communities, shareholders, employees, directors and other stakeholders. The Meeting will not be open to the general public and will be restricted to registered shareholders (who are also strongly discouraged from attending) and duly appointed proxyholders only. To ensure compliance with public health guidance on public gatherings, registered shareholders who wish to attend the Meeting are required to provide the Company with at least 48 hours advance notice, and any shareholder who does not provide such notice and receive approval from the Company to attend will not be admitted to the Meeting. Notice can be provided at IR@35.183.62.152.

To allow shareholders to follow the conduct of the Meeting, the Company is providing an audio teleconference that can be used by participants to listen to the Meeting in real time.

Teleconference Details

Date: Monday June 28, 2021

Time: 2:00 p.m. EST

North American Toll Free: 1-888-664-6383

Conference ID: 94023704

Please note that shareholders will not be entitled to vote at, or otherwise participate in, the Meeting by way of teleconference or other electronic means, and so this year, more than ever, we strongly encourage shareholders to vote in advance of the Meeting in accordance with the instructions provided in the materials for the Meeting, including the Management Information Circular, which has been mailed to shareholders and is available on SEDAR as well as the Company’s website.  

There will be no formal question and answer period following the Meeting and presentation by management, however, shareholders are welcome to submit questions in advance to the Investor Relations inbox at IR@35.183.62.152, and the Company will respond to select questions submitted before June 21, 2021 on the call.

ON BEHALF OF THE BOARD

“Hugo Alves” CEO

About Auxly Cannabis Group Inc. (TSX: XLY)

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team: 

Email: IR@35.183.62.152

Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:

Email: press@35.183.62.152 

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

TORONTO, May 28, 2021 — Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“) today released its financial results for the three months ended March 31, 2021. These filings and additional information regarding Auxly are available for review on SEDAR at www.sedar.com.

Q1 2021 Highlights and Subsequent Events

• — Recorded net revenues of $10M for the three months ended March 31, 2021, an increase of 1% from the same period in 2020.
• — Maintained leadership position in Cannabis 2.0 product sales with approximately 12.6% national market share¹ in the quarter.
• — SG&A declined another 5% from the previous quarter.
• — Continued to launch new innovative products to the Canadian market with the introduction of the Company’s first cannabis concentrate, 232 Series Diamonds under its Kolab Project brand and an industry-leading, high-potency topical, Dosecann Daily Relief CBD cream.
• — Welcomed Andrea Fraser to the Auxly Family as Chief People Officer.
• — Further strengthened the Company’s balance sheet with a $8M private placement offering of units.

Read full release on GlobeNewswire here.

Auxly Financials and Filings.

TORONTO, May 27, 2021 — Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a leading consumer packaged goods company in the cannabis products market, announced today that it has entered into a definitive agreement with Myconic Capital Corp. (NEO: MEDI) (“Myconic”), an investment issuer with a diversified portfolio focused on emerging companies, pursuant to which Myconic will acquire all of the issued and outstanding shares of KGK Science Inc. (“KGK”) (the “Transaction”) for up to $16.5 million in value comprised of:

• $12.5 million purchase price from Myconic in the form of:
  • $1.5 million in cash payable on the closing date of the Transaction;
  • $1.0 million in cash payable six months after the closing date of the Transaction; and
  • $10.0 million in common shares in the capital of Myconic (“Myconic Shares”) at a price per Myconic Share of $1.55 (being 6,451,612 Myconic Shares) all to be issued on the closing date of the Transaction, with equal tranches becoming freely tradeable on the four, six, nine and 12 month anniversaries of the closing date of the Transaction;

• $1.5 million milestone payment, payable in cash or Myconic Shares, at the option of Myconic, if KGK achieves gross revenues of $8 million in any 12-month period during the two years following the closing date of the Transaction; and
• $2.5 million credit against future KGK services, reflected in a 10-year service agreement between Auxly and KGK.

The Transaction is expected to close on or around the week of June 7, 2021 and is subject to customary closing conditions and regulatory approvals, including the approval of the NEO Exchange.

“This agreement with Myconic is a win-win for Auxly and its shareholders in both the short and long-term, as the additional capital can be deployed into our core business and accelerates Auxly’s path to profitability, while continuing our long-standing relationship with KGK to leverage their deep clinical expertise as we continue to bring innovative cannabis products to market that meet our consumer promise of quality, safety and efficacy,” said Hugo Alves, CEO, Auxly. “KGK is an outstanding CRO that knows how to unlock value in emerging industries through clinical work and will be an excellent fit with the team at Myconic.”

“This is an exciting day for KGK as we look to bring our years of experience as a leading CRO into the field of psychedelics research, which holds great promise for helping people overcome a wide range of illnesses,” said Najla Guthrie, President & CEO, KGK. “We’ve gained invaluable insight from our partnership with Auxly and look forward to continuing our relationship and helping them bring safe and effective cannabis products to market.”

“The investment that Myconic is making to acquire KGK is very exciting and I look forward to welcoming the KGK team and their valuable expertise to our company,” said Robert Meister, Chief Executive Officer of Myconic. “On behalf of the Board of Directors, I would like to commend Auxly on their professionalism and transparency throughout the Transaction thus far and look forward to our companies working together for many years into the future, long after the closing date,” added Mr. Meister.

With the sale of KGK, Auxly gains additional liquidity to support the Company’s ongoing commercial operations as it continues to expand its product offering in Canada and execute on its business strategy.

ON BEHALF OF THE BOARD
“Hugo Alves” CEO

About Myconic Capital Corp. (CSE: MEDI)

Myconic Capital Corp is an investment issuer with a diversified portfolio that is focused on emerging companies active in the high-tech, real estate, cannabis, mining and health and wellness sectors.

About Auxly Cannabis Group Inc. (TSX: XLY)

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team: 
Email: IR@35.183.62.152
Phone: 1.833.695.2414

Media Enquiries (only): 

For media enquiries or to set up an interview please contact:
Email: press@35.183.62.152 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the receipt of the necessary regulatory approval for the Transaction and the timing of such approval; the timing and proposed completion of the Transaction; the Company’s execution of its product development and commercialization strategy; consumer preferences; political change, future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: the Transaction can be completed on the anticipated terms and timeline; and general economic, financial market, regulatory and political conditions in which the Company operates will remain the same. Additional risk factors are disclosed in the annual information form of the Company for the financial year ended December 31, 2020 dated April 23, 2021.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on Auxly’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party industry sources, the accuracy of which has not been verified by Auxly. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this release. 

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise. 

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

TORONTO, May 20, 2021 — Auxly Cannabis Group Inc. (“Auxly” or the “Company”) (TSX: XLY) (OTCQX: CBWTF) is pleased to announce that it has closed its previously announced private placement offering of units (the “Units“) to an institutional investor (the “Investor”) for gross proceeds of approximately $8.0 million (the “Offering”). Pursuant to the Offering, the Company issued 23,880,598 Units of the Company at a price of $0.335 per Unit. ATB Capital Markets Inc. acted as exclusive agent on the Offering.

Each Unit is comprised of one common share of the Company (each a “Common Share“) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant entitles the Investor to purchase one Common Share at an exercise price of $0.42 at any time up to 36 months from closing of the Offering.

The net proceeds from the Offering will be used for working capital and general corporate purposes.

No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

ON BEHALF OF THE BOARD 

“Hugo Alves“ CEO 

About Auxly Cannabis Group Inc. (TSX: XLY)

Auxly is a vertically integrated cannabis company dedicated to bringing branded cannabis products to market that consumers love and trust. Our team of professionals and cannabis enthusiasts are united by a shared commitment to quality and our consumers. We build powerful value propositions with brands that connect and products that deliver on our consumer promise of quality, safety and efficacy.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Email: IR@35.183.62.152 
Phone: 1.833.695.2414

Media Enquiries (only): 
For media enquiries or to set up an interview please contact:
Email: press@35.183.62.152  

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the expected use of proceeds of the Offering; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

TORONTO, May 13, 2021 — Auxly Cannabis Group Inc. (“Auxly” or the “Company”) (TSX: XLY) (OTCQX: CBWTF) is pleased to announce that it has entered into an agreement with an institutional investor (the “Investor”) pursuant to which the Investor has agreed to purchase, on a private placement basis, 23,880,597 units (the “Units“) of the Company at a price of $0.335 per Unit for aggregate gross proceeds of approximately $8.0 million (the “Offering“). ATB Capital Markets Inc. is acting as exclusive agent on the Offering.

Each Unit shall be comprised of one common share of the Company (each a “Common Share“) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “Warrant“). Each Warrant shall entitle the Investor to purchase one Common Share at an exercise price of $0.42 at any time up to 36 months from Closing (as defined below).

The net proceeds from the Offering will be used for working capital and general corporate purposes.

The closing of the Offering is expected to occur during the week of May 17, 2021 (the “Closing”), or such later or earlier date as the Investor and the Company may agree upon, and is subject to the completion of formal documentation and the Company receiving all necessary regulatory approvals, including the approval of the Toronto Stock Exchange. The Units will be offered pursuant to applicable exemptions from the prospectus requirements of Canadian securities laws and shall be subject to a customary four-month hold period under Canadian securities laws.

No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.   This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

ON BEHALF OF THE BOARD 

“Hugo Alves“ CEO 

About Auxly Cannabis Group Inc. (TSX: XLY)
Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry-first movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Email: IR@35.183.62.152
Phone: 1.833.695.2414

Media Enquiries (only): 
For media enquiries or to set up an interview please contact:
Email: press@35.183.62.152 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the proposed completion of, and the expected use of proceeds of, the Offering; the Company’s response to the COVID-19 pandemic; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.
Additional risk factors are disclosed in the annual information form of the Company for the financial year ended December 31, 2020 dated April 23, 2021.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward‐looking information.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

 TORONTO, Ontario, May 5, 2021 – Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a leading consumer packaged goods company in the cannabis products market, is pleased to announce that it has hired Andrea Fraser as Chief People Officer. In this new role, Ms. Fraser will lead all aspects of the Company’s human resources, including crafting talent acquisition strategies, promoting inclusion in the workplace and further developing and evaluating career paths to meet the Company’s business goals. Ms. Fraser will also manage Auxly’s ongoing response to the impacts of COVID-19 as it relates to its employees and office spaces. 

Ms. Fraser brings extensive experience and deep knowledge of leading People and Culture strategy and initiatives for multinational CPG and digital marketing companies, most recently working as Director, Global Human Resources at Tilray. 

“We are delighted to welcome Andrea to the Auxly Family,” said Hugo Alves, CEO of Auxly. “We believe she is the right leader to help us continue building an engaged, inclusive and high-performing culture at Auxly.” 

Ms. Fraser commented, “I couldn’t be more excited to be joining Auxly as its new Chief People Officer. The highly engaged culture that Auxly has created is truly special and I look forward to helping them take these strengths to a new level of performance and success.” 

ON BEHALF OF THE BOARD 

“Hugo Alves” CEO 

About Auxly Cannabis Group Inc. (TSX: XLY) 

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market. 

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations: 

For investor enquiries please contact our Investor Relations Team: 

Email: IR@35.183.62.152 

Phone: 1.833.695.2414 

Media Enquiries (only): 

For media enquiries or to set up an interview please contact: 

Email: press@35.183.62.152 

Notice Regarding Forward Looking Information: 

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the Company’s response to the COVID-19 pandemic; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally. 

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise. 

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Ms. Fraser brings extensive experience and deep knowledge of leading People and Culture strategy and initiatives for multinational CPG and digital marketing companies, most recently working as Director, Global Human Resources at Tilray. 

“We are delighted to welcome Andrea to the Auxly Family,” said Hugo Alves, CEO of Auxly. “We believe she is the right leader to help us continue building an engaged, inclusive and high-performing culture at Auxly.” 

Ms. Fraser commented, “I couldn’t be more excited to be joining Auxly as its new Chief People Officer. The highly engaged culture that Auxly has created is truly special and I look forward to helping them take these strengths to a new level of performance and success.” 

ON BEHALF OF THE BOARD 

“Hugo Alves” CEO 

About Auxly Cannabis Group Inc. (TSX: XLY) 

Auxly is a leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market. 

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/. 2 

Investor Relations: 

For investor enquiries please contact our Investor Relations Team: 

Email: IR@35.183.62.152 

Phone: 1.833.695.2414 

Media Enquiries (only): 

For media enquiries or to set up an interview please contact: 

Email: press@35.183.62.152 

Notice Regarding Forward Looking Information: 

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the Company’s response to the COVID-19 pandemic; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally. 

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise. 

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. 

View on GlobeNewswire here.

TORONTO, Ontario, May 3, 2021 – Today Dosecann, an in-house brand owned by Auxly Cannabis Group Inc. (TSX – XLY) (“Auxly”), announces the launch of Dosecann Daily Relief CBD Cream, a new, high-strength, differentiated cannabis topical cream for Canadian wellness consumers. With 1,200mg of cannabidiol (CBD) per 60 ml unit, Dosecann Daily Relief CBD Cream has double the potency of any CBD topical currently available in the Canadian marketplace and is competitively priced to deliver the best value for a CBD topical[i]. Dosecann Daily Relief CBD Cream is available to order now for wholesalers across Canada, is available to consumers now in British Columbia and Saskatchewan and will also be available in Alberta in coming weeks.  

Dosecann Daily CBD Cream was developed by a team of scientists, researchers and formulation experts at Auxly’s state-of-the-art laboratory in Charlottetown, PEI, under the direction of Dr. Bob Chapman, Chief Science Officer, Dosecann.

“Topicals were among the very first products we conceived of at Dosecann and I’m extremely proud that after thorough development and testing, we’ve landed on a formula that we believe is the best in the marketplace,” said Dr. Chapman. “Consumers use topicals to provide daily relief from a wide variety of symptoms such as localized pain relief, muscle soreness, tension and inflammation. Our team was driven to ensure that Dosecann Daily Relief CBD Cream offers industry-leading potency along with a formulation designed to boost CBD penetration and provide the skin moisturizing properties of high-end skin creams.”

“We’re excited to launch Dosecann Daily Relief CBD Cream and expand our expertise in the 2.0 segment into topicals,” said Brad Canario, Brand Director, Auxly. “We know from research that topicals are a high-frequency segment, with nearly 50% of topical consumers using daily, and further, that amongst Canadian cannabis users, creams are the #1 topicals format. We believe we have a truly differentiated product for wellness consumers looking for daily relief from a variety of symptoms and, as always, we focused on our pillars of quality, safety and efficacy at every stage of product development.”

The proprietary Dosecann Daily Relief CBD Cream formula combines high-quality CBD extract with Natralipid™ Meadowfoam seed oil, a plant-based emollient found in high-end skin creams and valued for moisturization, transdermal barrier repair, skin penetration and unsurpassed stability. The result is a product that promotes the fast, effective absorption of high-quality CBD extract so that the cannabinoids can get where they’re needed quickly, all the while soothing the skin by locking-in moisture without leaving a greasy feeling behind. Dosecann Daily Relief CBD Cream has a mild, neutral bamboo scent and is packaged in a recyclable glass jar with a built-in seal to preserve freshness. 

Dosecann Daily Relief CBD Cream is the latest cannabis 2.0 release from Auxly, who achieved the #1 market-share position for Cannabis 2.0 products in 2020. With today’s launch, Dosecann expands its offering of natural, science-backed products, which includes oils and precision-dosed capsules made with omega-rich Ahiflower™ oil.

About Dosecann          
Dosecann is a world-class developer of innovative cannabis products for the wellness-focused consumer, wholly owned by Auxly Cannabis Group Inc.  Proudly processed at Auxly’s 52,000 sq. ft., state-of-the-art facility in Charlottetown, Prince Edward Island, Dosecann products are developed and manufactured on-site by a world-class team of scientists and experts, ensuring high-quality, precision and consistency. Dosecann’s wellness products, available at licensed cannabis retailers across Canada, consist of non-GMO capsules and oils. Built on the pillars of quality, safety and efficacy, Dosecann is cannabis – down to a science.

Learn more at dosecann.com and stay up to date at Twitter: @Dosecann; Instagram: @dosecann; Facebook: @dosecann.

About Auxly Cannabis Group Inc. (TSX: XLY) (OTCQX: CBWTF)  
Auxly is leading Canadian cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

For more information please contact:
Scott Campbell, 647-402-4957, press@35.183.62.152 

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes but is not limited to: Dosecann’s execution of its product development and commercialization strategy; consumer preferences; political change, future legislative and regulatory developments involving cannabis, cannabis products and cannabis health products; and competition and other risks affecting Auxly in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to whether: there is acceptance and demand for current and future Dosecann products by consumers and provincial purchasers, and general economic, financial market, regulatory and political conditions in which Auxly operates will remain the same. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party sources, the accuracy of which has not been verified by Auxly. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock  Exchange) accepts responsibility for the adequacy or accuracy of this release.